---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-005198"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2024-01-18T23:59:59+00:00"
generated_at: "2026-06-06T22:03:50.269135+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Surrozen discontinues SZN-1326; SZN-043 Phase 1a complete, data due Q1 2024

## Summary
- SZN-043 Phase 1a enrollment in chronic liver disease and healthy volunteers complete; safety/pharmacodynamic data expected Q1 2024.
- Phase 1b for alcohol-associated hepatitis to initiate soon; proof-of-concept data possible in H2 2024.
- SZN-1326 development in IBD discontinued due to asymptomatic grade 3 ALT/AST elevations at high doses and strategic factors.
- No serious adverse events in SZN-1326 trial; transaminase elevations resolved spontaneously in all subjects.

## SEC filing metadata
- accession: 0000950170-24-005198
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2024-01-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017024005198/0000950170-24-005198-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017024005198/srzn-20240118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-005198
- JSON: https://secwatch.observer/filing/0000950170-24-005198.json
- Plain text: https://secwatch.observer/filing/0000950170-24-005198.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.